Abstract:Abstract Neuronal injury, aging, and cerebrovascular and neurodegenerative diseases such as cerebral infarction, Alzheimer's disease, Parkinson's disease, frontotemporal dementia, amyotrophic lateral sclerosis, and Huntington's disease are characterized by significant neuronal loss. Unfortunately, the neurons of most mammals including humans do not possess the ability to self-regenerate. Replenishment of lost neurons becomes an appealing therapeutic strategy to reverse the disease phenotype. Transplantation of pluripotent neural stem cells can supplement the missing neurons in the brain, but it carries the risk of causing gene mutation, tumorigenesis, severe inflammation, and obstructive hydrocephalus induced by brain edema. Conversion of neural or non-neural lineage cells into functional neurons is a promising strategy for the diseases involving neuron loss, which may overcome the above-mentioned disadvantages of neural stem cell therapy. Thus far, many strategies to transform astrocytes, fibroblasts, microglia, Müller glia, NG2 cells, and other glial cells to mature and functional neurons, or for the conversion between neuronal subtypes have been developed through the regulation of transcription factors, polypyrimidine tract binding protein 1 (PTBP1), and small chemical molecules or are based on a combination of several factors and the location in the central nervous system. However, some recent papers did not obtain expected results, and discrepancies exist. Therefore, in this review, we discuss the history of neuronal transdifferentiation, summarize the strategies for neuronal replenishment and conversion from glia, especially astrocytes, and point out that biosafety, new strategies, and the accurate origin of the truly converted neurons in vivo should be focused upon in future studies. It also arises the attention of replenishing the lost neurons from glia by gene therapies such as up-regulation of some transcription factors or down-regulation of PTBP1 or drug interference therapies.

In situ Chemical Reprogramming of Astrocytes into Neurons: A New Hope for the Treatment of Central Neurodegenerative Diseases?

Progress of Reprogramming Astrocytes into Neuron

Progress and Challenges of Cell Replacement Therapy for Neurodegenerative Diseases Based on Direct Neural Reprogramming

Stem Cells for the Treatment of Neurodegenerative Diseases

In vivo chemical reprogramming of astrocytes into neurons

Astrocyte-to-neuron reprogramming and crosstalk in the treatment of Parkinson's disease

The therapeutic potential of cell identity reprogramming for the treatment of aging-related neurodegenerative disorders

Reprogrammed Astrocytes As a Potential Therapy for Neurodegenerative Disorders.

A Promise for Neuronal Repair: Reprogramming Astrocytes into Neurons in Vivo

Cellular Reprogramming and Its Potential Application in Alzheimer’s Disease

Neuronal conversion from glia to replenish the lost neurons

Reprogramming Astrocytes to Motor Neurons by Activation of Endogenous Ngn2 and Isl1

The Neuro-Inflammatory Microenvironment: an Important Regulator of Stem Cell Survival in Alzheimer’s Disease

Optogenetic Manipulation of Astrocytes from Synapses to Neuronal Networks: A Potential Therapeutic Strategy for Neurodegenerative Diseases

Astrocytic reprogramming combined with rehabilitation strategy improves recovery from spinal cord injury.

Recent Advances: Decoding Alzheimer’s Disease with Stem Cells

Remodeling Neurodegeneration: Somatic Cell Reprogramming-Based Models of Adult Neurological Disorders

Somatic Cell Reprogramming for Nervous System Diseases: Techniques, Mechanisms, Potential Applications, and Challenges

In Vivo Reprogramming Using Yamanaka Factors in the CNS: A Scoping Review

Direct Cell Reprogramming and Phenotypic Conversion: An Analysis of Experimental Attempts to Transform Astrocytes into Neurons in Adult Animals

Nanoparticle-mediated conversion of primary human astrocytes into neurons and oligodendrocytes